Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) stock closed at 2.2 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 109.71K shares and market capitalization of 105.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Entasis Therapeutics Holdings Inc. CEO is Manoussos Perros.

The one-year performance of Entasis Therapeutics Holdings Inc. stock is -20.58%, while year-to-date (YTD) performance is 0.46%. ETTX stock has a five-year performance of %. Its 52-week range is between 1.4 and 3.8799, which gives ETTX stock a 52-week price range ratio of 32.26%

Entasis Therapeutics Holdings Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 6.30, a price-to-sale (PS) ratio of 11.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -106.70%, a ROC of -127.80% and a ROE of -169.78%. The company’s profit margin is -%, its EBITDA margin is -660.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Entasis Therapeutics Holdings Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Entasis Therapeutics Holdings Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Entasis Therapeutics Holdings Inc. is Moderate Buy (2.5), with a target price of $3.25, which is +47.73% compared to the current price. The earnings rating for Entasis Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Entasis Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Entasis Therapeutics Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.47, ATR14 : 0.03, CCI20 : 172.47, Chaikin Money Flow : -0.03, MACD : 0.06, Money Flow Index : 51.80, ROC : 0.92, RSI : 70.91, STOCH (14,3) : 100.00, STOCH RSI : 0.91, UO : 62.42, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Entasis Therapeutics Holdings Inc. in the last 12-months were: David Altarac (Sold 3 759 shares of value $11 991 ), Elizabeth M. Keiley (Sold 3 759 shares of value $11 991 ), John Mueller (Sold 4 001 shares of value $12 763 ), Manoussos Perros (Sold 35 922 shares of value $114 591 ), Matthew Ronsheim (Sold 3 759 shares of value $11 991 ), Michael Gutch (Sold 3 759 shares of value $11 991 ), Ruben Tommasi (Sold 3 759 shares of value $11 991 )